Morgan Stanley Reiterates Underweight on Genmab, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison reiterated an Underweight rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.

June 12, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley analyst Matthew Harrison reiterated an Underweight rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.
The Underweight rating by Morgan Stanley analyst Matthew Harrison indicates a negative outlook for Genmab's stock price in the short term. The maintained $33 price target suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100